O R I G I N A L P A P E R
Serpentine supravenous hyperpigmentation related
to carboplatin and vinorelbine chemotherapy: A case report
Fatma Tuncez Akyurek
1| Nihal Sari
1| Ceyhan Ugurluoglu
2| Gulcan Saylam Kurtipek
11
Faculty of Medicine, Department of Dermatology, Selcuk University, Konya, Turkey
2
Faculty of Medicine, Department of Pathology, Selcuk University, Konya, Turkey Correspondence
Fatma Tuncez Akyurek, Faculty of Medicine, Department of Dermatology, Selcuk University, Konya, Turkey. Email: dermafatma@yahoo.com.tr
Abstract
Serpentine supravenous hyperpigmentation (SSH) is a unique type of
chemotherapy-associated drug eruption, characterized by hyperpigmentation along the superficial
venous network. Histopathology reveals an increase in melanin production without
destruction of basal cells of the epidermis or dermal inflammatory infiltrate. Herein,
we describe a patient who developed SSH after repeated intravenous infusions with
carboplatin and vinorelbine; two medications that have been uncommonly reported
in association with SSH previously.
K E Y W O R D S
carboplatin, chemotherapeutic agent, serpentine supravenous hyperpigmentation
1
| I N T R O D U C T I O N
Hyperpigmentation is an established cutaneous adverse effect of che-motherapeutic agents (Reyes-Habito, 2014). Serpentine supravenous hyperpigmentation (SSH) is a novel and specific type of cutaneous pigmented drug eruption caused by intravenous injection or infusion of some chemotherapeutic agents (Jamalpur, 2017; Payne, 2006). It is a rare complication of chemotherapy, clinically characterized by linear or serpentine streaks of hyperpigmentation following the traces of veins through which the antineoplastic agent has been infused or injected. As the clinical presentation is unique, it can easily be distin-guished from other types of drug-induced pigmentation (Roach, 2015). The most commonly reported offender medication for SSH in medical literature is 5-flourouracil monotherapy. However, other antineoplastic agents including alkylating agents, antibiotics, anti-microtubules, and proteasome inhibitors or a combination of these agents have also been reported as culprits (Geddes, 2010). In our case, carboplatin and vinorelbine were held responsible for SSH; two medications that have rarely been associated with SSH.
2
| C A S E R E P O R T
A 52-year-old male patient undergoing chemotherapy with car-boplatin and vinorelbine for non-small cell lung cancer was admitted
to our outpatient clinic with complaints of redness, pain, and exuding wounds on the hands and arms. Approximately 2 weeks after the first course of chemotherapy, the patient had developed painful erythema-tous lesions beginning from the infusion site and spreading to the right arm. This initial presentation has been interpreted as drug extravasation. Topical treatment of this condition led to regression in erythema; however, the pigmentation remained. Two days after the second course of chemotherapy, painful erythematous lesions devel-oped on the dorsal aspect of the left hand, extending from the infu-sion site to the left forearm. Dermatologic examination revealed tender erythematous and bullous lesions in a linear and serpentine pattern of distribution conforming to superficial venous network, over the dorsum of the left hand and left arm (Figures 1 and 2). There was no evidence of lymphadenopathy, superficial venous thrombosis, thrombophlebitis, or extravasation injury in the axillary region. A skin biopsy sample obtained on the fifth day following the second infusion showed loss of superficial epidermis, perivascular and dermal lympho-cytic infiltration, focal edema, and scant extravasated erythrocytes (Figure 3). Topical steroids, boric acid dressings, and oral nonsteroidal anti-inflammatory therapy led to amelioration of erythematous and bullous lesions within a few days, at site of which linear hyper-pigmented tracts remained corresponding to the veins of left forearm (Figure 4).
Received: 6 March 2019 Revised: 24 May 2019 Accepted: 3 June 2019 DOI: 10.1111/dth.12981
Dermatologic Therapy. 2019;32:e12981. wileyonlinelibrary.com/journal/dth © 2019 Wiley Periodicals, Inc. 1 of 4 https://doi.org/10.1111/dth.12981
3
| D I S C U S S I O N
Erythematous or hyperpigmented linear eruptions following trauma to superficial veins at the injection site have been reported with various chemotherapeutic agents. The terms “persistent supravenous ery-thematous eruption” (PSEE), “persistent supravenous hyperpigmented eruption” (PSHE), and “serpentine supravenous hyperpigmentation” (SSH) have been used to define such drug eruptions (Aydogan, 2005; Payne, 2006). PSEE is characterized by erythematous streaks or
red-violet-colored papules and plaques in a linear or serpentine pattern following the superficial venous network near the infusion site (Aydogan, 2005; Chen, 2005; Ghosh, 2011; Spencer, 1984). It is most F I G U R E 1 Erythematous bullous eruption at the site of infusion
on the left hand and erythematous to hyperpigmented linear and serpentine eruption overlying the superficial venous network
F I G U R E 2 Linear erythematous and bullous lesions located along the superficial vein traces of the left forearm
F I G U R E 3 Histopathological portrait of a biopsy specimen obtained from a supravenous erythematobullous lesion demonstrating loss of superficial epidermis, perivascular and dermal lymphocytic infiltration, focal edema, and scant extravasated erythrocytes (hematoxylin–eosin stain; high magnification 20 × 10)
F I G U R E 4 Regression of erythematobullous lesions left residual hyperpigmented linear and serpentine bands
commonly seen over the forearm (Geddes, 2010). Lesions develop within 24 hr to 15 days after intravenous cytotoxic drug infusion and spontaneously transform into residual hyperpigmented bands overly-ing the venous network within 1–3 weeks; this phase of the eruption is reminiscent of PSHE/SSH (Aydogan, 2005; Koehn, 1982; Payne, 2006). Unlike superficial venous thrombosis or thrombophlebitis, the veins involved in PSEE or PSHE/SSH remain patent (Chan, 2010; Ghosh, 2011). The eruption may resolve within 1 to few months after termination of chemotherapy, although persistent eruptions have also been reported (Aydogan, 2005; Chan, 2010; Payne, 2006). After repeated intravenous exposure to the responsible drug, the eruption may recur or hyperpigmentation may increase in intensity (Aydogan, 2005; Chen, 2005; Fine, 1986; Koehn, 1982; Marcoux, 2000; Spencer, 1984). In our case, the reaction developed after both the first and second courses of carboplatin and vinorelbine chemotherapy, starting as PSEE and progressing into PSHE/SSH after a few days.
Although the histological features of PSEE and PSHE/SSH are not diagnostic, biopsy in PSEE reveals isolated necrotic keratinocytes at all levels of the epidermis, vacuolar change of basal epithelium, mild edema of the underlying papillary dermis, and perivascular infiltrate in the papillary dermis (Aydogan, 2005). It has been reported that spongiosis and occasional dyskeratotic cells might have been in the epidermis (Spencer, 1984). Given this histopathological appearance, some authors have described PSEE as an erythema multiforme-like drug reaction. In contrast, PSHE/SSH displays diffuse basilar melanin pigmentation, marked basilar dendritic melanocytes, occasional necrotic keratinocytes, scant melanophages in the papillary dermis, and slight perivascular lymphocytic infiltrates (Aydogan, 2005; Ghosh, 2011; Jain, 2005; Rao, 2010).
Thus, clinically and histologically PSEE is distinguished from PSHE/SSH by the presence of a painful or pruritic erythematous inflammatory phase, vacuolar change, destruction of basal cells, necrotic keratinocytes, and perivascular inflammatory infiltrate in the former. In contrast, PSHE/SSH is characterized by an asymptomatic pigmented rash, with a histological portrait of increased dendritic melanocytes, increased melanin granules, and lack of basal cell destruction or prominent inflammatory infiltrate (Aydogan, 2005; Cecchi, 1994; Ghosh, 2011; Jain, 2005; Rao, 2010). However, PSEE lesions become hyperpigmented by time and eventually take the look of PSHE/SSH clinically (Aydogan, 2005). We believe that the distinc-tion between PSHE and PSHE/SSH is blurred and that the latter rep-resents the abortive (or invisible subclinical) phase of the former.
SSH has a gender predilection as it is nine times more frequently reported in men than in women. The age range varies between 7 and 85 years, with a mean of 46 years (Geddes, 2010). SSH was initially described by Hrushesky in 1975 as a rare side effect of intravenous 5-fluorouracil administration (Hrushesky, 1976). Thereafter, other agents have also been implicated as a cause of this eruption (Ghosh, 2011; Payne, 2006; Rao, 2010). The list of medications reported in association with PSEE, PSHE/SSH encompasses 5-fluorouracil, doce-taxel, paclidoce-taxel, fotemustine, bromodeoxyuridine, vinorelbine, vinblas-tine, vincrisvinblas-tine, nitrogen mustard, cyclophosphamide, dactinomycin, doxorubicin, daunorubicin, 6-mercaptopurine, bleomycin, dacarbazine,
and bortezomib (Ghosh, 2011; Jamalpur, 2017; Payne, 2006; Rao, 2010). To our knowledge, there have been three cases vinorelbine-induced SSH (Cecchi, 1994; Marongiu, 2009; Roach, 2015) and no report of carboplatin-associated SSH in the literature. Our case repre-sents the fourth case of vinorelbine-associated SSH and first case of carboplatin-associated SSH.
The mechanism of this peculiar drug-induced supravenous pig-mentation pattern is obscure. Theories involve direct toxic effect of the medication on the vascular endothelium that enhances loss of vas-cular integrity and increased vasvas-cular permeability, possible extra-vasation/leakage of the medication from traumatized vein(s), and its direct toxic and/or stimulating effects over the surrounding neighbor-ing epidermal melanocytes (Chan, 2010; Lang, 2002; Payne, 2006; Rao, 2010; Susser, 1999). In fact, most of the offender medications have been linked to significant extravasation injuries previously (Chen, 2005; Payne, 2006). Inadequate venous washing may be responsible for the injury to vascular endothelium (Aydogan, 2005). Adequate venous washing has been reported to prevent the occurrence of SSH. Along with termination of the offender medication, pentoxifylline has been recommended as a potential hemorheologic therapeutic option (Aydogan, 2005; Chen, 2005).
Parallel to an increase in the frequency of malignancies and emer-gence of new chemotherapeutic agents, dermatologists will more fre-quently encounter SSH and other chemotherapy-induced cutaneous adverse effects in clinical daily practice. Being aware of rare and novel cutaneous chemotherapy-associated reactions will enable physicians to guide management and treatment of affected patients accordingly.
O R C I D
Fatma Tuncez Akyurek https://orcid.org/0000-0002-9339-8331
Gulcan Saylam Kurtipek https://orcid.org/0000-0002-3106-4280
R E F E R E N C E S
Aydogan, I. (2005). Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel. Journal of the European Academy of Dermatology and Venereology, 19(3), 345–347.
Cecchi, R. (1994). Supravenous hyperpigmentation induced by vinorelbine. Dermatology, 188(3), 244–244.
Chan, C. C. (2010). Images in clinical medicine. Serpentine supravenous hyperpigmentation. New England Journal of Medicine, 363(5), e8. Chen, G. Y. (2005). Sclerotic and retracted supravenous
hyper-pigmentation associated with combination chemotherapy for meta-static breast carcinoma. The British Journal of Dermatology, 152(6), 1383–1385.
Fine, J. D. (1986). Distinctive eruption characterized by linear supravenous papules and erythroderma following broxuridine (bromodeoxyuridine) therapy and radiotherapy. Archives of Dermatology, 122(2), 199–200. Geddes, E. R. (2010). Antineoplastic agent-associated serpentine
supra-venous hyperpigmentation: Superficial venous system hyper-pigmentation following intravenous chemotherapy. Southern Medical Journal, 103(3), 231–235.
Ghosh, S. K. (2011). Letter: Docetaxel-induced supravenous serpentine dermatitis. Dermatology Online Journal, 17(11), 16.
Hrushesky, W. J. (1976). Serpentine supravenous fluorouracil hyper-pigmentation. JAMA, 236(2), 138–138.
Jain, V. (2005). Serpentine supravenous streaks induced by 5-fluorouracil. Journal of the American Academy of Dermatology, 53(3), 529–530. Jamalpur, I. (2017). Serpentine supravenous hyperpigmentation. Clinical
Case Reports, 5(9), 1546–1547.
Koehn, G. G. (1982). Unusual local cutaneous reaction to dacarbazine. Archives of Dermatology, 118(12), 1018–1019.
Lang, K. (2002). Supravenous hyperpigmentation, transverse leuconychia and transverse melanonychia after chemotherapy for Hodgkin's dis-ease. Journal of the European Academy of Dermatology and Venereology, 16(2), 162–163.
Marcoux, D. (2000). Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomy-cin and vincristine. Journal of the American Academy of Dermatology, 43 (3), 540–546.
Marongiu, P. (2009). Chemotherapy-induced persistent serpentine supra-venous hyperpigmented eruption and persistent supra-supra-venous ery-thematous eruption: Case report. Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Societa Italiana di Dermatologia e Sifilografia, 144(1), 97–100.
Payne, A. S. (2006). Dermatologic toxicity of chemotherapeutic agents. Seminars in Oncology, 33(1), 86–97.
Rao, R. (2010). Serpentine supravenous pigmentation. A rare vasculocutaneous effect induced by systemic 5-fluorouracil. Indian Journal of Dermatology, Venereology and Leprology, 76(6), 714–715. Reyes-Habito, C. M. (2014). Cutaneous reactions to chemotherapeutic drugs
and targeted therapies for cancer: Part I. conventional chemotherapeutic drugs. Journal of the American Academy of Dermatology, 71(2), 203–e1. Roach, E. C. (2015). Serpentine supravenous hyperpigmentation resulting
from vinorelbine administration. The Breast Journal, 21(3), 311–312. Spencer, H. J. (1984). Local erythema multiforme-like drug reaction
follow-ing intravenous mitomycin C and 5-fluorouracil. Journal of Surgical Oncology, 26(1), 47–50.
Susser, W. S. (1999). Mucocutaneous reactions to chemotherapy. Journal of the American Academy of Dermatology, 40(3), 367–398.
How to cite this article: Akyurek FT, Sari N, Ugurluoglu C, Kurtipek GS. Serpentine supravenous hyperpigmentation related to carboplatin and vinorelbine chemotherapy: A case report. Dermatologic Therapy. 2019;32:e12981.https://doi. org/10.1111/dth.12981
